LONDON--(BUSINESS WIRE)--The Cell Therapy Catapult has announced four separate collaborations with multiple-partners to deliver health and wealth to the UK through support from Innovate UK, formerly the Technology Strategy Board.
The agreement with Plasticell is a further investment in a therapeutic programme utilising CombiCult®, the high throughput stem cell technology designed to solve bottlenecks in regenerative medicine development. The consortium also includes the University of Oxford. This will allow the group to develop a process to expand cord blood stem cells ex vivo using Plasticell’s media, allowing more patients to be treated with potentially life-saving therapies.
Help employers find you! Check out all the jobs and post your resume.
